Table 3.

GCLLSG Prognostic Index

Score5-y survival, %
Biomarker  
 Age, y   
  ≤60  
  >60  
 Sex   
  Female  
  Male  
 ECOG PS   
  0  
  >0  
 β2-microglobulin, mg/L   
  ≤1.7  
  1.7-3.5  
  >3.5  
 Serum thymidine kinase, U/L   
  ≤10  
  >10  
 IGHV  
  Mutated  
  Unmutated  
 11q22-q23   
  Nondeleted  
  Deleted  
 17p13   
  Nondeleted  
  Deleted  
Risk group   
 Low risk 1-2 95 
 Intermediate risk 3-5 86 
 High risk 6-10 67 
 Very-high risk 11-14 18 
Score5-y survival, %
Biomarker  
 Age, y   
  ≤60  
  >60  
 Sex   
  Female  
  Male  
 ECOG PS   
  0  
  >0  
 β2-microglobulin, mg/L   
  ≤1.7  
  1.7-3.5  
  >3.5  
 Serum thymidine kinase, U/L   
  ≤10  
  >10  
 IGHV  
  Mutated  
  Unmutated  
 11q22-q23   
  Nondeleted  
  Deleted  
 17p13   
  Nondeleted  
  Deleted  
Risk group   
 Low risk 1-2 95 
 Intermediate risk 3-5 86 
 High risk 6-10 67 
 Very-high risk 11-14 18 

ECOG PS, Eastern Cooperative Oncology Group performance status; GCLLSG, German CLL Study Group.